NCT05556226

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigned to one of the 2 treatment groups. Approximately 40 adult healthy volunteers will be enrolled in 2 sites in the United States. All participants will receive ABBV-154 as subcutaneous injections with one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 9 days. Adverse Events and blood tests will be performed.

Conditions

• ABBV-154

Interventions

Type	Name	Description
DRUG	ABBV-154 Dose Formulation A	Subcutaneous Injection
DRUG	ABBV-154 Dose Formulation B	Subcutaneous Injection

Timeline

• Start date: 2022-10-18
• Primary completion: 2023-02-17
• Completion: 2023-02-17
• First posted: 2022-09-27
• Last updated: 2023-03-13

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study